Author name: Leonardo Arias

Unos científicos han ideado y fabricado un pequeño dispositivo médico inyectable que introduce en la ciencia médica un nuevo enfoque para el tratamiento del dolor crónico y de los trastornos del movimiento, controlando la actividad nerviosa sin necesidad de cirug&i …

Unos científicos han ideado un modo de usar aquafaba (el líquido resultante de cocer legumbres) y aceites vegetales para obtener grasas sólidas más saludables que la mantequilla, la margarina o la grasa de palma y capaces de reemplazar por completo a estas en productos de …

Uno de los mayores retos de la robótica social actual es conseguir que las máquinas interactúen con nosotros de forma natural y personalizada. Para lograrlo, una de las formas es que el robot sepa con quién está hablando.   El grupo de robótica social …

The FDA cited problems with some of Zoll’s ventilators, automated external defibrillators and electrodes.

Employers are considering raising premiums and increasing other forms of cost sharing as they grapple with stubbornly rising health costs, according to a new survey from Mercer.

Joint Commission leaders break down the standards group’s new AI certification, explaining how it’s designed to work for everyone from major health systems to small rural clinics.

UniQure’s planned third-quarter submission for its Huntington’s disease gene therapy may be a harbinger of a more flexible FDA under acting commissioner Kyle Diamantas—but how long will it last? And how can companies be sure these positive decisions won’t just be reversed?

The international launch could benefit from Boston Scientific’s global footprint when the company closes its takeover of Penumbra.

The drug middlemen lobby has had a busy week. It’s the second major lawsuit the PCMA has filed against a state law reforming the PBM industry since Monday.

In this episode of Denatured, you’ll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We explore how recessive dystrophic epidermolysis bullosa has become a defining case study for gene and cell therapy and what this ultra‑rare disease reveals about the future scalability of advanced